Dose-volume analysis of planned versus accumulated dose as a predictor for late gastrointestinal toxicity in men receiving radiotherapy for high-risk prostate cancer

Ashley L.K Ong a, b, *, Kellie Knight b, Vanessa Panettieri b, c, Mathew Dimmock b, d, Jeffrey K.L Tuan a, Hong Qi Tan a, Caroline Wright b

a National Cancer Centre Singapore, Division of Radiation Oncology, Singapore
b Monash University, Department of Medical Imaging and Radiation Sciences, Clayton, Australia
c Alfred Hospital, Alfred Health Radiation Oncology, Melbourne, Australia
d Keele University, School of Allied Health Professions, Staffordshire, UK

A R T I C L E   I N F O
Keywords: Accumulated dose Predictive model Gastrointestinal toxicity High-risk prostate Volumetric image-guidance

A B S T R A C T

Background and purpose: Significant dose deviations have been reported between planned (Dp) and accumulated (Da) dose in prostate radiotherapy. This study aimed to develop multivariate analysis (MVA) models associating Grade 1 and 2 gastrointestinal (GI) toxicity with clinical and Dp dosimetric variables separately.

Materials and methods: Dose volume (DV) metrics were compared between Dp and Da for 150 high-risk prostate cancer patients. MV models were generated from significant clinical and dosimetric variables (p < 0.05) at univariate level. Dose-based-region of interest (DB-ROI) metrics were included. Model performance was measured, and additional subgroup analysis were performed.

Results: Rectal Dp demonstrated a higher intermediate-high dose (V30-65 Gy) and DB-ROI at 15–50 mm) compared to Da. Conversely, at the very high dose region, rectal Dp (V75 Gy) and DB-ROI at 5–10 mm) were significantly lower. In MVA, rectal DB-ROI at 10 mm was predictive for Grade ≥1 GI toxicity for Dp and Da. Age, rectal Dp for Dp >30 cc, and rectal Da for DB-ROI 10 mm were predictors for Grade 2 GI toxicity. Subgroup analysis revealed that patients ≥ 72 years old and a rectal Dp of ≥ 78.2 Gy were highly predictive of Grade 2 GI toxicity.

Conclusions: The dosimetric impact of a higher dose rectal dose in Dp due to volumetric changes was minimal and was not predictive of detrimental clinical toxicity apart from rectal Dp >30 cc ≥ 78.2 Gy for Grade 2 GI toxicity. The use of the DB-ROI method can provide equivalent predictive power as the DV in toxicity prediction.

1. Introduction

External beam radiotherapy combined with androgen deprivation therapy is the recommended clinical management for locally advanced high-risk prostate cancer (HR-PCa) [1]. As prostate cancer exhibits a low α/β value (1.5 Gy) which is comparable to that of late responding tissues [2], there’s a shift towards the use of dose escalation and hypofractionated regimens to improve the overall therapeutic ratio [3,4]. This is especially critical for HR-PCa because of the high likelihood of mutation to a lethal phenotype that could reduce the biochemical and local control rate [5]. However, the drawback of these treatment schemes is often associated with a decline in patients’ quality of life as the incidence of reported gastrointestinal (GI) toxicity remains significant despite the use of advanced radiotherapy technologies [6,7].

Significant volumetric variations of the organs at risk (OARs) that could affect the actual delivered dose during prostate RT have been reported [8,9]. Small cohort studies demonstrated significant dose differences between accumulated dose (Da) obtained from either daily megavoltage computed tomography (MVCT) or repeated CT scans and planned dose (Dp) [10,11]. Majority of the large cohort studies focusing on the correlations between the rectal dose with the risk of late GI complications were mainly based on the dose distributions obtained with three-dimensional conformal radiation therapy (3D-CRT) techniques [12,13]. Although some work has been done on evaluating the risk of GI toxicity with Da generated based on patients’ cone-beam computed tomography (CBCT) scans, they were mainly performed on
prostate only cases without the inclusion of pelvic lymph nodes (PLNs) [14,15]. There is a paucity of work evaluating the dose difference in $D_A$ and $D_B$ on HR-PCa patients with PLNs irradiation using patients’ daily CBCT scans to assess the impact of inter-fractional organ motion on the risk of developing GI toxicity. In addition to the dosimetric variables, GI toxicity has also been demonstrated to be affected by patient-related factors, comorbidities, and intake of medications. Acute GI symptoms occurring within three months of treatment were also found to be significantly correlated with the incidence of late GI toxicity [7,16].

In this study, we hypothesized that multivariate (MV) models generated that incorporate $D_A$ together with clinical factors are more predictive than $D_B$ values in associating late GI toxicity in HR-PCa with prophylactic pelvic lymph nodes (PLNs) irradiation. The objectives of this study were firstly, to evaluate the difference between $D_A$ and $D_B$ for the prostate and rectum using the previously developed dose accumulation workflow. Secondly, to construct MV models with Grade $\geq 1$ and Grade $\geq 2$ late GI toxicity as clinical endpoints whereby $D_A$ and $D_B$ were analysed separately with clinical variables. Lastly, subgroup analysis was performed on significant predictors that were correlated to the increased occurrence of late GI toxicity derived from the MV models.

2. Materials and methods

In this study, a total of 150 HR-PCa patients who were treated at our institution with PLN-irradiation between January 2016 and December 2019 were retrospectively recruited. The median follow-up (FU) for the entire cohort was 41.9 months, ranging from 16.3 to 62.1 months. Ethics approval was obtained from the centralised institutional review board (CRIB ref: 2019/2018). Patients’ characteristics, acute and late toxicity profiles are presented in Table 1.

2.1. CT-simulation and treatment planning

All patients were simulated in a supine position, using a leg immobiliser, with arms on their chests. Patients were advised by the radiation therapist on the bladder filling protocol (2–3 cups; 400–600 ml of water 30–60 mins before the procedure) and to empty their bowels before CT-simulation and during daily treatment. CT simulation was undertaken with 2.5 mm slice thickness (120kVp, GE LightSpeed RT 16).

A sequential (two-phase) treatment regimen was utilised, whereby a dose of 46–54 Gy in 23–27 fractions was prescribed to the prostate, seminal vesicles (SVs), and PLNs in Ph1. A coned-down Ph2 volume with a dose of 24–28 Gy in 12–14 fractions was delivered to the proximal 1 cm of the SVs and prostate, giving a total of 74–78 Gy. For Ph1, clinical target volumes (CTVs) were defined as the entire prostate and SVs with superior border set at L5/S1 interspace (including the distal common iliac, internal, and external iliac nodes). Ph1 planning target volume (PTV) was obtained by using an expansion margin of 5 mm posteriorly and 5–8 mm in all other directions. Ph2 PTV was generated by performing an isotropic 5 mm expansion from Ph2 CTV. All cases were planned with a 10 MV energy dual arc volumetric modulated arc therapy (VMAT) technique.

2.2. Dose based-region of interest (DB-ROI) structure

Apart from the standard DV variables, mean doses obtained from the alternative DB-ROI method were used as additional dosimetric variables for model building. The details of the generation of these structures were reported previously [17]. Briefly, DB-ROI structures were created by performing a volumetric expansion based on steps of 5 mm (5–50 mm) from the surface of the prostate gland. For each ROI expanded contour, the area of the previous smaller shape was subtracted from its area to yield strips of 5 mm structures at increasing distances from the prostate. The mean dose generated from the intersection of the 5 mm structures with the rectum was defined as $D_x$ mm, whereby $x$ ranged from 5 to 50 mm. This novel ROI method can account for the volumetric changes of the rectum at a specific distance from the prostate surface in a consistent manner, thus having the potential to overcome the uncertainties in visualizing the various rectal segments that were reported to contribute to toxicity [18,19].

\begin{table}[h]
\centering
\caption{Patients’ characteristics, acute and late toxicity profiles.}
\begin{tabular}{|l|c|c|}
\hline
Characteristics & N = 150 cases (\%) & \\
\hline
Age at diagnosis, yrs.; median [IQR] & 72 [68.75] & \\
BMI, kg/m$^2$; median [IQR] & 24.3 [22.5–26.4] & \\
Gleason score; median [IQR] & 8 [7.9] & \\
$\leq 7$ & 62 (41.3 \%) & \\
$> 7$ & 86 (57.3 \%) & \\
Not known & 2 (1.3 \%) & \\
\hline
CT-stage (AJCC 8th edition) & \\
$\leq 2b$ & 75 (50 \%) & \\
$> 2b$ & 75 (50 \%) & \\
Baseline PSA (ng/mL); median [IQR] & 26.6 [11.7–55.5] & \\
\hline
Medications & \\
Anti-hypertensive & \\
Yes & 74 (49.3 \%) & \\
No & 76 (50.7 \%) & \\
Metformin & \\
Yes & 33 (22 \%) & \\
No & 117 (78 \%) & \\
Statins & \\
Yes & 52 (34.7 \%) & \\
No & 98 (65.3 \%) & \\
TURP & \\
Yes & 13 (8.7 \%) & \\
No & 136 (90.7 \%) & \\
Not known & 1 (0.7 \%) & \\
ADT & \\
$\leq 6$ months & 39 (26 \%) & \\
$> 6$ months & 111 (74 \%) & \\
RT prescription & \\
$\leq 74$ Gy & 88 (58.7 \%) & \\
$> 74$ Gy & 62 (41.3 \%) & \\
\hline
Organ volumes & \\
Prostate vol. (cm$^3$); median [IQR] & 31.9 [24.4–42.6] & \\
Rectum vol. (cm$^3$); median [IQR] & 45.3 [36.2–57.4] & \\
\hline
Overall acute toxicity & \\
Grade $\geq 1$ & 53 (35.3 \%) & \\
Grade $\geq 2$ & 12 (8 \%) & \\
\hline
Late toxicity & \\
Diarhoea & \\
Grade 1 & 1 (0.7 \%) & \\
Grade 2 & 10.7 \%) & \\
Rectal hemorrhage & \\
Grade 1 & 29 (19.3 \%) & \\
Grade 2 & 9 (6 \%) & \\
Proctitis & \\
Grade 1 & 16 (10.7 \%) & \\
Grade 2 & 9 (6 \%) & \\
Overall late toxicity & \\
Grade $\geq 1$ & 45 (30 \%) & \\
Grade $\geq 2$ & 13 (8.7 \%) & \\
\hline
\end{tabular}
\end{table}

Abbreviations: BMI = body mass index, AJCC = American Joint Committee on Cancer antigen, PSA = prostate specific antigen; TURP = transurethral resection of the prostate; ADT = androgen deprivation therapy; GI = gastrointestinal; IQR = interquartile range.

The rectum at a specific distance from the prostate surface in a consistent manner, thus having the potential to overcome the uncertainties in visualizing the various rectal segments that were reported to contribute to toxicity [18,19].

2.3. Treatment localisation and dose accumulation workflow

Daily CBCT scans were acquired in the treatment position using a half-fan mode (45 cm field-of-view, 120 kVp) scan, and reconstructed to 2.5 mm slice thickness (Varian on-board imaging v2.1, Varian Medical Systems, Palo Alto, CA) as part of the image localization protocol before treatment delivery. A total of 37–39 CBCTs images were available per patient to perform dose accumulation. A customised dose accumulation workflow was developed using MIM (MIMVista® v6.9, MIM Software Inc., Cleveland OH, USA) [20]. Details of the workflow construction and validation of an intensity-based deformable image registration (DIR) algorithm used in MIM have been described in our recent publication.
Late GI toxicity (diarrhoea, rectal haemorrhage and proctitis) was documented after three months post-RT, six-monthly for five years and yearly thereafter. In this study, the overall maximum occurrence of Grade $\geq 1$ and Grade 2 GI toxicity determined at 2 years post-RT follow-up (FU) was considered as the clinical endpoints to be investigated. Majority of the toxicity records were documented electronically within the radiation-oncology-specific record and verification information system (Mosaiq; Elekta, Stockholm, Sweden). GI toxicity was graded according to the Radiation Therapy Oncology Group (RTOG) criteria. Approximately 20% of the records were extracted and documented from free-text input from Mosaiq and patient’s physical case notes. Toxicity records were also re-populated, reviewed and verified in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03; CTCAE) by the radiation oncologist from the study team.

2.4. GI toxicity assessments and documentations

The primary clinical outcome of this study was the occurrence of Grade $\geq 1$ and Grade 2 GI toxicity measured at two years post-RT FU. Descriptive statistics (e.g., means $\pm$ standard deviation, medians with interquartile ranges) were presented as appropriate. For the dosimetric analysis comparing $D_A$ and $D_P$, a parametric paired t-test was used after performing a normality test (Shapiro-Wilk test). A p-value $< 0.05$ being deemed significant. Highly correlated variables were filtered using Pearson correlation test ($r \geq 0.8$) [21]. Univariate logistic analysis (UVA) was performed on individual clinical and dosimetric variables to define associations with late clinical endpoints. Significant variables at the UVA level (p $< 0.05$) were used for the subsequent multivariate logistic regression analysis (MVA) using an enter/remove method to identify the independent predictors for the final MV model, whereby p $< 0.05$ was considered statistically significant [22]. Results were reported as odds ratios, 95% confidence intervals (CIs) and p-values.

Model performance was measured with respect to its calibration results and discriminative ability. Hosmer-Lemeshow p-value (p-HL) goodness of fit test was used to generate the calibration plot in which a p-value of $> 0.05$ indicates that the observed and predicted probability is similar, and therefore a good model fit is achieved [19]. For binary dependent variables, the observed outcomes were divided into quartiles to attain the observed probabilities and were plotted against the predicted probabilities. Model discrimination was assessed using the mean area under the receiver operating characteristic curve (AUC) to determine the overall model fit of the predictors with respect to the defined clinical endpoints. Achieving an AUC of $\geq 0.6$ and having a minimum 95% CI $\geq 0.5$ were considered statistically significant by Guifford et al [23]. Internal validation was accomplished using bootstrapping techniques to obtain the best fit predictors with associated 95% CI as described in published studies [24,25]. Lastly, subgroup analysis was conducted on MVA predictors using the AUC curve to determine the most relevant threshold differentiating the defined toxicity [26]. All analyses were performed using SPSS statistics (IBM Corp. v27.0, Armonk, NY) and R software (https://www.r-project.org/, version 4.0, Vienna, Austria).

3. Results

3.1. Dose-volume analysis between $D_A$ and $D_P$ for prostate and rectum

Absolute mean DV values for $D_A$, $D_P$ and the difference in mean dose; ($D_A - D_P$), Gy for the prostate and rectum are presented in Table 2. For the prostate, $D_{\text{V39 Gy}}^{\text{ROI 5-50 mm}}$ coverage for $D_A$ and $D_P$ were statistically insignificant (p = 0.53). For the rectum, the $D_A$ was significantly higher on average at the intermediate-high dose range; $D_{\text{V50 Gy}}^{\text{ROI 30-65 Gy}}$, with a $\geq 0.5$ Gy difference being observed at the intermediate dose region ($D_{\text{V45 Gy}}^{\text{ROI 30-45 Gy}}$). On the contrary, at the very high dose region, $D_A$ was significantly higher compared to $D_P$ ($D_{\text{V60 Gy}}^{\text{ROI 0-15 mm}}$, p $< 0.001$ and $D_{\text{V75 Gy}}^{\text{ROI 0-15 mm}}$, p $< 0.001$).

3.2. Dose-based ROI analysis between $D_A$ and $D_P$ for the rectum

The absolute mean DV values for rectal $D_A$, $D_P$ and the difference in dose; ($D_A - D_P$), Gy were calculated for all patients per ROI; $D_{\text{V30-50 mm}}^{\text{ROI rect}}$, ($5-50$ mm from the prostate surface) and were shown in Table 3. $D_{\text{V30-50 mm}}^{\text{ROI rect}}$ received a higher dose (1.4 – 3.6 Gy) compared to $D_{\text{V15-30 mm}}^{\text{ROI rect}}$ and were statistically significant (p $< 0.001$). On the contrary, at $D_{\text{V5-10 mm}}^{\text{ROI rect}}$, $D_A$ on average was significantly lower compared to $D_P$ (p $< 0.001$).

3.3. MV modelling and model performance evaluation.

In the MV modelling, the correlations of clinical variables were tested separately with each of the two dosimetric variables $D_A$ and $D_P$ (see Table 4). Four statistically significant models (p $< 0.05$) were generated based on the significant predictors obtained from the UVAs, associated with the development of Grade $\geq 1$ and Grade 2 late GI toxicity. A complete list of UVA results is available in supplemental table (Table S1). All statistically significant MV models achieved an AUC of $\geq 0.6$ and a minimum 95% CI $\geq 0.5$, meeting the stated criteria for good model performance (Table S2). Similarly, all four models attained a p-HL of $> 0.5$ as demonstrated in the calibration plots (Fig. 1), suggesting that the predicted probability coincides well with the observed events.

3.4. MV regression analysis of Grade 1 and Grade 2 GI toxicity at 2 years post-RT FU

For Grade $\geq 1$ late GI toxicity using clinical and $D_A$ or $D_P$ assessment, $D_{\text{V45 Gy}}^{\text{ROI 10 mm}}$ ($D_A$: OR: 1.13 vs $D_P$: OR: 1.17) and $D_{\text{V50 Gy}}^{\text{ROI 5-50 mm}}$ ($D_A$: OR: 0.97 vs $D_P$: OR: 0.96) were significant dosimetric predictors associated with the development Grade $\geq 1$ GI toxicity for $D_A$ and $D_P$. The same AUC value of 0.67 was achieved for Models 1 and 1a. None of the clinical predictors were significant for these models. For Grade $\geq 2$ late GI toxicity using clinical and $D_A$ and $D_P$ assessment, age was a significant clinical predictor (OR: 1.15, p $< 0.01$) in Models 2 and 2a. Additionally, $D_{\text{V0.03 cc}}^{\text{ROI 10 mm}}$ (Model 2, $D_A$: OR: 1.34) and $D_{\text{V0.03 cc}}^{\text{ROI 10 mm}}$ (Model 2a, $D_A$: OR: 1.35) remained as significant dosimetric predictors with age in both models; attaining overall high AUC values of 0.78 and 0.81 for Model 2 and 2a respectively (Table 4).

3.5. Subgroup analysis

Based on the MV models, five predictors defined by an associated increased in occurrence of late GI toxicity were further evaluated to determine the optimal cut-off values using the AUC curve. Cut-off values with the highest sensitivity and lowest specificity were selected. As shown in Table S3, patients who were $\geq 72$ years old (AUC: 0.86, p $< 0.05$; 95 % CI: 0.53–0.82) were 3.6 times more likely to experience Grade $\geq 2$ GI toxicity at 2 years post-RT FU (UVA: p $< 0.05$, CI: 0.95–3.6) compared to those younger than 72 years old. Similarly, patients with an accumulated dose, $D_A$ $\geq 78.2$ Gy (AUC: 0.67, p $< 0.05$; 95 % CI: 0.65–0.80) delivered to 0.03 cc of the rectum were 4.8 times more likely to suffer from Grade $\geq 2$ GI toxicity (UVA: p $< 0.01$, CI: 1.39–16.29) compared to those receiving $< 78.2$ Gy to 0.03 cc of the rectal volume. The rest of the predictors remained statistically insignificant. 

\[D_A - D_P\]
insignificant in UVA after applying the selected cut-off values for the defined toxicity.

### 4. Discussion

This study hypothesised that for HR-PCa patients undergoing PLNs irradiation, MV models obtained using a dose accumulation workflow to generate $D_{A}$ together with clinical factors, are more predictive than $D_{P}$ for late GI toxicity. Apart from incorporating the pertinent clinical variables to predict the occurrence of Grade ≥ 1 and Grade 2 late GI toxicity, $D_{A}$ received by the rectum (which accounted for daily inter-fractional organ motion) further enhanced the predictive power of the developed models [15]. This study is one of the largest dose comparative series to date, incorporating $D_{A}$ as the dosimetric variable used to perform MV modelling for late GI toxicity in HR-PCa patients treated with the highly conformal VMAT technique.

For Models 1 and 1a, the $D_{R010mm}$ parameter represents the segment of the rectum that is close to the prostate high dose region and was associated with an increased risk of Grade ≥ 1 GI toxicity [27]. $D_{V50 Gy}$ for $D_{A}$ and $D_{P}$ was significant in Grade ≥ 1 GI toxicity in MV modelling. Splashes of low doses to the rectum, which increases due to the inclusion of PLNs irradiation has negligible impact on the risk of having Grade ≥ 1 GI toxicity as demonstrated in this study. Despite having a significantly higher percentage of rectum volume receiving 35 Gy in $D_{A}$, which could be attributed to the occurrence of rectal distension at the superior portion of the rectum as previously reported [17,28], it does not have a parallel impact on rectal toxicity. Similarly, results reported by Vargass et al [29], on associating DV metrics with late Grade 2 GI toxicity concluded that relative volume of rectum irradiated to ≤ 40 Gy was not predictive for this toxicity endpoint.

For Models 2 and 2a, advanced age is highly associated with the increasing risk of Grade 2 GI toxicity, which is in parallel to reported studies [30,31]. In Model 2, the interactions with age and $D_{A03cc}$ demonstrated good model performance (AUC, 0.78, p < 0.001). Age and high dose to small volume of the rectum were often being reported as having a strong correlation to late Grade 2 GI toxicity [32]. Even though
Fig. 1. Calibration plots (predicted vs observed probabilities) for Grade $\geq 1$ GI (A) and Grade $\geq 2$ GI (B). The 45° dotted line represents the reference line where $y = x$.

$D_{A\text{DIFF}0.03cc}$ was significantly lower compared to $D_A$ in DV analysis due to potential reduction in rectal volume along the segment that lies directly posterior to the prostate, it has remained as a strong predictor in MV analysis. This further confirmed the underlining serial-like behaviour of the rectum that is highly correlated to the small rectal volume receiving $\geq 74$ Gy [28]. In Model 2a, age and $D_{ext}$ were highly predictive of patients suffering from late Grade 2 toxicity, achieving similar good model performance as Model 2 (AUC, 0.81, $p < 0.001$). The use of alternative DB-ROI structures that are closer to the prostate (5–10 mm) might be equivalent to the very high dose range (70-75 Gy) in routine DV scenarios. Educating the importance of having an empty rectum, dietary interventions and the use of laxatives have been suggested to maintain the consistency of a small rectal volume [33], thus minimising the risk of late GI toxicity.

In the subgroup analysis, $D_{A\text{DIFF}0.03cc}$ was the only significant predictor for Grade $\geq 2$ late GI toxicity whereby a dose limit of 78.2 Gy was recommended with a 4.8 times greater probability of developing this clinical endpoint for every 1 Gy increase in dose. This dose limit is parallel to the recommended values reported in studies investigating DV limits with GI toxicity [6,28]. Interfractional rectal motion might be minimal beyond the dose limit of 78.2 Gy and thus the toxicity event rates were low. Age $\geq 72$ years ($p < 0.05$) was the only significant clinical predictor for Grade $\geq 2$ late GI toxicity. Results obtained from a similar study conducted by Pederson et al. [34] also found that advanced age ($\geq 70$ years) correlates with an increased risk of late GI toxicity. Often, age is among the most important prognostic factors in guiding decision making with regards to patient expectations in terms of treatment aggressiveness with the aim for cure and expected treatment-related toxicity/quality of life.[35].

This study has some limitations. Firstly, external validation was not performed on the developed models. However, internal validation was conducted to examine model performance and met the robustness criteria whereby an average AUC of $\geq 0.6$ were achieved in all the MV models. Secondly, the relatively short late toxicity timeframe at two years post-RT FU might not be sufficient to capture the late toxicity effects as a latency period of delayed occurrence have been reported to be greater than 5 years [3,36,37]. However, in this study, as all patients have completed their 2 years post-RT FU, the derived models are highly predictive in determining late GI toxicity in HR-PCa patients at a two-year time-point.

The novelty of this work was to use the mean dose derived from the DB-ROIs as surrogates for various dose spectrums. These parameters were found to be highly predictive of late GI toxicity compared to the standard DV metrics as observed in the final MV models (Table 5). DB-ROI structures can be generated automatically in an unbiased manner using the prostate gland as the base structure and accounting for the patient-specific volumetric organ variations during RT. DB-ROI structures can complement the standard values for toxicity association, thereby reducing the challenges in identifying the specific region of the rectum that is associated with the defined toxicity [19].

Despite the higher dose at the intermediate-high dose region obtained in $D_A$, it does not translate into a corresponding increase in late Grade 2 GI toxicity. The use of modern radiotherapy techniques such as the use of more accurate magnetic resonance imaging-based target definition and the ability to generate smaller PTV margins from the utilisation of image guidance might have rendered the impact of volumetric changes of the OARs during RT insignificant. A larger sample size with a longer follow up will be necessary to determine the impact of volumetric changes on associated late toxicity and to substantiate the result of $D_{A\text{DIFF}0.03cc}$ being highly predictive of late Grade 2 GI toxicity. Lastly, this study could be further expanded to incorporate the use of dose surface maps for $D_A$ and $D_B$ and correlate with toxicity as voxel-level dose have been reported to improve the accuracy in identifying heterogeneous areas of heightened dose sensitivity [15,38].

In conclusion, the developed MV models for HR-PCa treated using inverse planning techniques to predict the risk of late GI toxicity at two years post-RT FU will be able to provide guidelines to facilitate dose escalation. In particular, this work has shown that patient age $> 72$ years and has an accumulated dose of $> 78.2$ Gy received by 0.03 cc of the rectum are significant predictors of Grade $\geq 2$ late GI toxicity.

**Funding statement**

This work was partially funded by Monash University, Medical Imaging and Radiation Sciences Higher Degree Research student fund, 2021 and the Duke-NUS Oncology Academic Program Goh Foundation Proton Research Programme (08/FY2021/EX(SL)/92-A146).

**Declaration of Competing Interest**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

**Appendix A. Supplementary data**

Supplementary data to this article can be found online at https://doi.org/10.1016/j.phro.2022.07.001.
References

[1] Bolla M, Henry A, Mason M, Wigiel T. The role of radiotherapy in localised and locally advanced prostate cancer. Asian J Urol 2019;6:153–61.

[2] van Leeuwen CM, Oei AL, Creaze J, Bel A, Franken NAP, Stalpers LJA, et al. The alpha and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies. Radiat Oncol 2018;13:796.

[3] Incrocci L, Wortel RC, Alemayehu WG, Aluwini S, Schimmel E, Krol S, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2016;17:1061–9.

[4] Pollack A, Walker G, Horwitz EM, Price R, Feigenberg S, Konski AA, et al. Randomized Trial of Hypofractionated External-Beam Radiotherapy for Prostate Cancer. J Clin Oncol 2013;31:3860–8.

[5] Rodríguez G, Warde P, Pickles T, Crook J, Brundage M, Souhami L, et al. Pre-treatment risk stratification of prostate cancer patients: a critical review. Can Urol Assoc J 2012;6:1217–7.

[6] Yu T, Zhang Q, Zheng T, Shi H, Liu Y, Feng S, et al. The effectiveness of intensity modulated radiation therapy versus three-dimensional radiation therapy in prostate cancer: a meta-analysis of the literatures. PLoS ONE 2016;11:e0154499.

[7] Peach MS, Showalter TN, Ohri N. Systematic review of the relationship between acute and late gastrointestinal toxicity after radiotherapy for prostate cancer. Prostate Cancer 2015;2015:624736.

[8] Pearson D, Gill SK, Campbell N, Reddy K. Dosimetric and volumetric changes in the rectum and bladder in patients receiving CBCT-guided prostate IMRT: analysis based on daily CBCT dose calculation. J Appl Clin Med Phys 2016;17:107–17.

[9] Casares-Magaz O, Muren LF, Pettersson N, Thor M, Hopper A, Knopp R, et al. A case-control study using motion-inclusive spatial dose-volume metrics to account for genito-urinary toxicity following high-precision radiotherapy for prostate cancer. Phys Imaging Radiat Oncol 2018;7:65–9.

[10] Thor M, Bentsen I, Hysing LB, Ekanger C, Helle SI, Karldottir Å, et al. Prediction of rectum and bladder morbidity following radiotherapy of prostate cancer based on motion-inclusive dose distributions. Radiother Oncol 2013;107:47–52.

[11] Scalfe JE, Thomas SJ, Harrison K, Romanichkova M, Sutcliffe MPF, Forman JR, et al. Accumulated dose to the rectum, measured using dose-volume histograms and dose-surface maps, is different from planned dose in all patients treated with radiotherapy for Br J Radiol 2015;88:20150243.

[12] Valdagni R, Rancati T, Fiorino C, Fellin G, Magli A, Baccolini M, et al. Development of a set of nomograms to predict acute lower gastrointestinal toxicity for prostate cancer 3D-CRT. Int J Radiat Oncol Biol Phys 2008;71:1065–73.

[13] Valdagni R, Kattan MW, Rancati T, Yu C, Vavassori V, Fellin G, et al. Is it time to tailor the prediction of radio-induced toxicity in prostate cancer patients? Building the first set of nomograms for late rectal syndrome. Int J Radiat Oncol Biol Phys 2012;82:1957–66.

[14] Shelley LEA, Scalfe JE, Romanichkova M, Harrison K, Forman JR, Bates AM, et al. Delivered dose can be a better predictor of rectal toxicity than planned dose in prostate radiotherapy. Radiother Oncol 2017;125:866–71.

[15] Casares-Magaz O, Bülow S, Pettersson NJ, Moiseenko V, Pedersen J, Thor M, et al. High accumulated doses to the inferior rectum are associated with late gastrointestinal toxicity in a case-control study using motion-inclusive spatial dose-volume metrics to account for genito-urinary toxicity following high-precision radiotherapy for prostate cancer. Phys Imaging Radiat Oncol 2018;17:107–9.

[16] Inokuchi H, Mizowaki T, Norihisa Y, Takayama K, Ikeda I, Nakamura K, et al. Association between voxel-level accumulated dose and rectal toxicity in a case-control study of prostate cancer patients treated with image-guided radiotherapy for patients with prostate cancer. Oncot Lett 2018;16:2741–9.

[17] Vargas C, Martínez A, Kestin LL, Yan D, Grillí I, Brabbins DS, et al. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. Int J Radiat Oncol Biol Phys 2005;62:1297–308.

[18] Hamstra DA, Stennmark MH, Ritter T, Litzenberg D, Jackson W, Johnson S, et al. Age and comorbid illness are associated with late rectal toxicity following dose escalated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2013;85:1246–53.

[19] Ospina JD, Zhu J, Chira C, Bosni A, Delobel J, Beckendorf V, et al. Random forests to predict rectal toxicity following prostate cancer radiation therapy. Int J Radiat Oncol Biol Phys 2014;89:1024–31.

[20] D’Avino V, Palma G, Liuzzi R, Conson M, Doria F, Salvatore M, et al. Prediction of gastrointestinal toxicity after external beam radiotherapy for localized prostate cancer. Radiother Oncol 2015;10:80.

[21] Teivel H, Solberg A, Lydersen S, Jensen CA, Kaasa S, Lund JÅ. Rectal volume variations and estimated rectal dose during 8 weeks of image-guided radical 3D conformal external beam radiotherapy for prostate cancer. Clin Transl Radiat Oncol 2019;15:113–7.

[22] Pederson AW, Fricano J, Coreia D, Pelizzari CA, Liaw SL. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity. Int J Radiat Oncol Biol Phys 2012;82:235–41.

[23] Jani AB, Parikh SD, Vijayakumar S, Gratze J. Analysis of influence of age on acute and chronic radiotherapy toxicity in treatment of prostate cancer. Urol 2005;65:1157–62.

[24] Dehmoley D, Sandikou I, Monop N, Kho V, Britte A, Bloomfield D, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 2016;17:1047–60.

[25] Inokuchi H, Mizowaki T, Norihisa Y, Taka A, Nakamura K, et al. Celecoxib, 5-Fluorouracil and capecitabine. N Engl J Med 2004;351:2399–400.

[26] Ong A, Knight K, Panettieri V, Dimmock M, Tuan JKL, Tan HQ, et al. Development of an automated radiotherapy dose accumulation workflow for locally advanced high-risk prostate cancer - A technical report. J Med Imaging Radiat Sci 2020;1:8–7.

[27] Midar S, Sarkar SK, Rana S. Collinearity diagnostics of binary logistic regression model. J Interdiscip Math 2010;13:253–67.

[28] Moiseenko V, Marks LB, Grim J, Jackson A, Milano MT, Hattangadi-Ghush JA, el Aziz et al. A primer on dose-response data modeling in radiation therapy. Int J Radiat Oncol Biol Phys 2021;10:11–20.

[29] Dehmoley D, Sandikou I, Monop N, Kho V, Britte A, Bloomfield D, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 2016;17:1047–60.

[30] Inokuchi H, Mizowaki T, Norihisa Y, Takayama K, Ikeda I, Nakamura K, et al. Correlation between urinary dose and delayed radiation cystitis after 78Gy intensity-modulated radiotherapy for high-risk prostate cancer: A 10-year follow-up study of genitourinary toxicity in clinical practice. Clin Transl Radiat Oncol 2019;7:31–4.

[31] Shelley LEA, Sutcliffe MPF, Thomas SJ, Noble DJ, Romanichkova M, Harrison K, et al. Associations between voxel-level accumulated dose and rectal toxicity in prostate radiotherapy. Phys Imaging Radiat Oncol 2020;14:87–94.